Short-term neoadjuvant hormone therapy enhanced expression of clusterin in prostate cancer.
- Author:
Yi-nong NIU
1
;
Dian-qi XIN
;
Zhi-song HE
;
Li-qun ZHOU
;
Bo-nian PAN
;
Yan-qun NA
;
Ying-lu GUO
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Clusterin; genetics; metabolism; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; methods; Oligonucleotides, Antisense; therapeutic use; Prostatic Neoplasms; metabolism; pathology; therapy
- From: Chinese Journal of Surgery 2005;43(6):394-397
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo define changes in clusterin expression following short-term neoadjuvant hormone therapy (NHT) and its biological significance in prostate cancer tissues.
METHODSTwenty-six archival radical prostatectomy (RP) specimens without receiving NHT, 19 needle biopsies and corresponding 19 RP specimens following 3-month NHT, were subjected to immunohistochemical clusterin staining.
RESULTSStaining for clusterin was mainly found in cytoplasm and part of extracellular matrix. Clusterin expression was significantly greater in RP specimens with preoperative NHT (t = 2.91, P < 0.01); Needle biopsies obtained before NHT consistently demonstrated lower staining intensity (1.42 +/- 0.51) than corresponding RP specimens (2.16 +/- 0.60) following 3-month NHT (t = 7.10, P < 0.01).
CONCLUSIONSUpregulation of clusterin in part accounts for malignant progression of prostate cancer through its anti-apoptotic action following androgen withdrawal. These findings support that adjuvant therapy targeting clusterin may enhance androgen ablation therapy in advanced prostate cancer.
